AllianceBernstein (AB)
(Delayed Data from NYSE)
$33.79 USD
-0.10 (-0.30%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $33.83 +0.04 (0.12%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth D Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AB 33.79 -0.10(-0.30%)
Will AB be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AB
AllianceBernstein (AB) May AUM Up on Favorable Markets, Inflows
AllianceBernstein's (AB) April AUM Falls on Market Depreciation
AB: What are Zacks experts saying now?
Zacks Private Portfolio Services
AB vs. SEIC: Which Stock Is the Better Value Option?
Are Finance Stocks Lagging Bain Capital Specialty Finance (BCSF) This Year?
Are Investors Undervaluing AllianceBernstein (AB) Right Now?
Other News for AB
US employers added a solid 206,000 jobs in June in a sign of continued economic strength
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
Ariel Investments Q1 2024 International (DM) Composite Strategy Letter
AllianceBernstein Invests in People With Its "Returnship" Program
Strong Buy Ratings and 5% Dividends: 7 Stocks That Will Boost Your Portfolio